Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

European Journal of Endocrinology

Volumn 161, Issue 1, 2009, Pages 1-9

  Hemmingsen, Bianca ^b   Lund, Søren S ^a   Wetterslev, Jørn ^b   Vaag, Allan ^a  

^a STENO DIABETES CENTER   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT;

ADD ON THERAPY; ALBUMINURIA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC DIET; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT PLANNING; ANIMAL; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR;

ADMINISTRATION, ORAL; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PREVALENCE; RISK FACTORS;

EID: 67650767021     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0167     Document Type: Review

References (55)

1. King H, Aubert RE & Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 21 1414-1431.
2. Vaag A. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights. Danish Medical Bulletin 1999 46 197-234.
3. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. American Journal of Medicine 2002 113 3S-11S.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R & Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 193-203.
5. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I & Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 30 1608-1610.
6. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E & Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999 22 756-761.
7. King GL & Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinology and Metabolism Clinics of North America 1996 25 255-270.
8. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ & Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. Journal of Biological Chemistry 2002 277 1794-1799.
9. Nigro J, Osman N, Dart AM & Little PJ. Insulin resistance and atherosclerosis. Endocrine Reviews 2006 27 242-259.
10. Lusis AJ. Atherosclerosis. Nature 2000 407 233-241.
11. Schneider DJ, Absher PM, Neimane D, Russell JC & Sobel BE. Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood. Diabetologia 1998 41 141-147.
12. Muniyappa R, Montagnani M, Koh KK & Quon MJ. Cardiovascular actions of insulin. Endocrine Reviews 2007 28 463-491.
13. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 854-865.
14. Davis BJ, Xie Z, Viollet B & Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006 55 496-505.
15. Mather KJ, Verma S & Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology 2001 37 1344-1350.
16. De JJ, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ & Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of Internal Medicine 2005 257 100-109.
17. Holman RR, Paul SK, Bethel MA, Matthews DR & Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 2008 359 1577-1589.
18. Lund SS, Rossing P & Vaag AA. Follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 2009 360 416.
19. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M & Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005 3 CD002966.
20. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B & Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2006 355 2427-2443.
21. Mellbin LG, Malmberg K, Norhammar A, Wedel H & Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. European Heart Journal 2008 29 166-176.
22. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag A. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism 2007 9 394-407.
23. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, Winther K, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag AA. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. European Journal of Endocrinology 2008 158 631-641.
24. Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag AA. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European Journal of Endocrinology 2008 158 35-46.
25. Johnson JA, Majumdar SR, Simpson SH & Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002 25 2244-2248.
26. Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE & Pogach LM. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007 30 1689-1693.
27. Rao AD, Kuhadiya N, Reynolds K & Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008 31 1672-1678.
28. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der BB, Donker AJ & Stehouwer CD. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002 25 2133-2140.
29. Kooy A, De JJ, Lehert P, Bets D, Wulffele MG, Donker AJ & Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Archives of Internal Medicine 2009 169 616-625.
30. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES & Veves A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003 52 173-180.
31. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U & Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 1279-1289.
32. Nordt TK, Peter K, Bode C & Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. Journal of Clinical Endocrinology and Metabolism 2000 85 1563-1568.
33. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T & Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. Journal of the American College of Cardiology 2005 45 1925-1931.
34. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT & Tan MH. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007 30 2458-2464.
35. Hsiao A, Worrall DS, Olefsky JM & Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004 20 3108-3127.
36. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC & Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. Journal of the American Medical Association 2006 296 2572-2581.
37. Betteridge DJ, DeFronzo RA & Chilton RJ. PROactive: time for a critical appraisal. European Heart Journal 2008 29 969-983.
38. Lincoff AM, Wolski K, Nicholls SJ & Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Journal of the American Medical Association 2007 298 1180-1188.
39. Nissen SE & Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007 356 2457-2471.
40. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N & Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005 48 1726-1735.
41. Uwaifo GI & Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. American Journal of Cardiology 2007 99 51B-67B.
42. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG & Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008 358 2545-2559.
43. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R & Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008 358 2560-2572.
44. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG & Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009 360 129-139.
45. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P & Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009 119 351-357.
46. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB & Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007 147 386-399.
47. Smits P, Bijlstra PJ, Russel FG, Lutterman JA & Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Research and Clinical Practice 1996 31 S55-S59.
48. Consoli A, Gomis R, Halimi S, Home PD, Mehnert H, Strojek K & Van Gaal LF. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes and Metabolism 2004 30 509-516.
49. Bloomgarden ZT. The Avandia debate. Diabetes Care 2007 30 2401-2408.
50. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P & Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 2005 353 2643-2653.
51. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC & Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 405-412.
52. Collins R, Armitage J, Parish S, Sleigh P & Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 2005-2016.
53. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J & Pyorala K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1999 159 2661-2667.
54. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E & Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366 895-906.
55. Gaede P, Lund-Andersen H, Parving HH & Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008 358 580-591.